Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.
Jeremy L. Ramdial, MD
Advertisement
Articles by Jeremy L. Ramdial, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
5